Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum

By sjmartinez • January 6, 2024

Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa Junior MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S; IMPAACT 2010/VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093/cid/ciae001. Epub ahead of print. PMID: 38180851.

Tags: adverse pregnancy outcomes, antepartum weight change, HIV, Infectious Diseases, postpartum weight, Publications, Women’s health

The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?

Thiagarajan K, Mishra S, Purdie R, Torres B, Johnson RH, Butte MJ. The Use of Genetics and Immunology in the Diagnosis and Care of Advanced[...]

Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2

Grinspoon SK, Zhao S, Martinez E, Fichtenbaum CJ, Chu SM, Diggs MR, Umbleja T, McCallum S, Fitch KV, Triant VA, Currier JS, Aberg JA, Malvestutto[...]

Preferences for HIV prevention conditional cash transfers among Black/African American and Latinx cisgender MSM in Los Angeles

Moucheraud C, Trujillo D, Wagner Z, Garland W, Smith T, Hoffman RM, Landovitz RJ. Preferences for HIV prevention conditional cash transfers among Black/African American and[...]